CytoMed Therapeutics Limited GDTC
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -32.09%
- 1 year
- -57.08%
- Market cap
- 10.86M
- Revenue (ttm)
- 447.69K
- EPS (ttm)
- -0.23
- Shares out
- 11.54M
- Forward P/E
- -15.80
- YTD return
- -32.09%
- 1-year return
- -57.08%
- Volume
- 5.18K
- Avg volume
- 19.51K
- Open
- 0.92
- Previous close
- 0.9098
- Day's range
- 0.852 – 0.92
- 52-week range
- 0.68 – 3.10
- Price target
- 5.00 (+449.5%)
6M -0.0870 (-8.73%)
Key statistics
- Enterprise value
- 23.15M
- PEG ratio
- 0.00
- Price / sales
- 61.09
- Price / book
- 2.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -21.10%
- Free cash flow
- -2.59M
- Total cash
- 6.82M
- Total debt
- 428.29K
- Return on equity
- -26.26%
- Short % of float
- 4.43%
- 50-day average
- 2.43
- 200-day average
- 2.06
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.03.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 10, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Jun 11, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Dec 4, 2023 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Jul 21, 2023 | Benchmark | init | — | Speculative Buy |
About CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Singapore
- Website
- w2.cytomed.sg
News
CytoMed Therapeutics Receives Nasdaq Noncompliance Notice 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
12 Health Care Stocks Moving In Monday's After-Market Session 
12 Health Care Stocks Moving In Friday's After-Market Session - 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Intraday Session - 9 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
Your note
Sign in to keep a note on GDTC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.00% | 61 | 144 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.04% | 4,854 | 11.50K | Oct 30, 2024 |